GlaxoSmithKline gets offers from potential buyers for drug plant in Brasov, Romania
UK-based drug manufacturer GlaxoSmithKline (GSK) has received offers from local and international investors to buy its Europharm factory in Brasov, Romania.
Earlier in 2013, the British firm decided to close the Europharm plant owing to excess capacities for solid oral drugs.
GSK Romania general manager Pascal Prigent was quoted by romania-insider.com as saying that the company has received more offers than expected and is currently in talks with potential buyers.
"The decision came following a wave of expired patents which led to an excess of capacity for solid oral drugs," Prigent said.
Though GSK intends to move production at the plant to its other factories it will, however, not put off further investment in Romania.
The company's Brasov plant which is the second largest drug producer in Romania posted a turnover of EUR104m and profit of EUR11m in 2012.
The Brasov facility, which employs about 250 people, is engaged in the manufacturing of drugs for HIV/AIDS treatments, respiratory diseases, depression, cold and flu.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250